After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

“Emphysema is part of a group of lung conditions which comes under the umbrella term chronic obstructive pulmonary disease ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

For those reliant on inhalers or other medications, Breathe presents a complementary ... For those struggling with asthma, COPD, or other respiratory issues, Breathe represents a promising option ...

Recently, tiotropium has been studied in asthma, when added to low-dose inhaled corticosteroids ... use of these drugs in asthma management. AUC: Area under the curve; COPD: Chronic obstructive ...

The September 11th attacks left an impact on individuals who lived, worked, or volunteered near Ground Zero. These ...